Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals (Nasdaq: TERN) announced the granting of equity inducement awards to a new employee under its 2022 Employment Inducement Award Plan. The grant, approved by the Company's Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4), includes options to purchase 9,000 shares of Terns common stock.
The options come with a 10-year term and an exercise price of $5.54 per share, matching Terns' closing stock price on December 31, 2024. The options will vest over a four-year period, contingent on the employee's continued service with the company.
Terns Pharmaceuticals (Nasdaq: TERN) ha annunciato l'assegnazione di premi di indennità azionaria a un nuovo dipendente nell'ambito del suo Piano di Indennità Occupazionale 2022. Il premio, approvato dal Comitato per la Compensazione della Società in conformità con la Regola di Quotazione Nasdaq 5635(c)(4), include opzioni per l'acquisto di 9.000 azioni ordinarie di Terns.
Le opzioni hanno un termine di 10 anni e un prezzo di esercizio di $5.54 per azione, corrispondente al prezzo di chiusura delle azioni di Terns del 31 dicembre 2024. Le opzioni saranno acquisibili in un periodo di quattro anni, a condizione che il dipendente continui a prestare servizio presso la società.
Terns Pharmaceuticals (Nasdaq: TERN) anunció la concesión de premios de incentivos de capital a un nuevo empleado bajo su Plan de Premios de Incentivo de Empleo 2022. La concesión, aprobada por el Comité de Compensación de la Compañía de acuerdo con la Regla de Listado de Nasdaq 5635(c)(4), incluye opciones para comprar 9,000 acciones ordinarias de Terns.
Las opciones tienen un plazo de 10 años y un precio de ejercicio de $5.54 por acción, coincidiendo con el precio de cierre de las acciones de Terns del 31 de diciembre de 2024. Las opciones se adquirirán a lo largo de un período de cuatro años, sujeto a la continuación del servicio del empleado con la empresa.
턴스 제약회사 (Nasdaq: TERN)는 2022 고용 유인 보상 계획에 따라 새로운 직원에게 주식 유인 보상을 지급한다고 발표했습니다. 이 보상은 Nasdaq 상장 규칙 5635(c)(4)를 준수하여 회사 보상 위원회에서 승인되었으며, 9,000주의 턴스 보통주를 구매할 수 있는 옵션을 포함합니다.
이 옵션은 10년 유효기간과 $5.54의 행사가격을 가지며, 이는 2024년 12월 31일 턴스의 주가 마감 가격과 일치합니다. 이 옵션은 직원이 회사에 지속적으로 근무하는 조건으로 4년 동안 분할하여 부여됩니다.
Terns Pharmaceuticals (Nasdaq: TERN) a annoncé l'octroi de récompenses incitatives en actions à un nouvel employé dans le cadre de son Plan de Récompenses d'Emploi 2022. L'octroi, approuvé par le Comité de Rémunération de l'Entreprise conformément à la Règle de Cotation Nasdaq 5635(c)(4), comprend des options pour acheter 9 000 actions ordinaires de Terns.
Les options ont une durée de 10 ans et un prix d'exercice de 5,54 USD par action, correspondant au prix de clôture des actions de Terns au 31 décembre 2024. Les options seront acquises sur une période de quatre ans, sous réserve de la continuité du service de l'employé au sein de la société.
Terns Pharmaceuticals (Nasdaq: TERN) gab die Gewährung von Eigenkapitalanreizprämien an einen neuen Mitarbeiter im Rahmen seines Arbeitsanreizprämienplans 2022 bekannt. Die Gewährung, die vom Vergütungsausschuss des Unternehmens gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt wurde, umfasst Optionen zum Kauf von 9.000 Aktien des Stammkapitals von Terns.
Die Optionen haben eine Laufzeit von 10 Jahren und einen Ausübungspreis von 5,54 USD pro Aktie, der dem Schlusskurs der Terns-Aktien am 31. Dezember 2024 entspricht. Die Optionen werden über einen Zeitraum von vier Jahren fällig, abhängig von dem fortgesetzten Dienst des Mitarbeiters im Unternehmen.
- None.
- None.
FOSTER CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of January 1, 2025 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equity award was approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee’s acceptance of employment with Terns.
The Company granted options to purchase 9,000 shares of Terns common stock to the new employee. The options have a 10-year term and an exercise price per share equal to
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com
FAQ
What is the exercise price of TERN's new employee stock options granted on January 1, 2025?
How many shares were included in TERN's January 2025 employee inducement grant?
What is the vesting period for TERN's January 2025 employee stock options?
What is the term length of the stock options granted by TERN in January 2025?
